IL108147A - APOD-L ethyl ester preparations and their preparation - Google Patents

APOD-L ethyl ester preparations and their preparation

Info

Publication number
IL108147A
IL108147A IL10814793A IL10814793A IL108147A IL 108147 A IL108147 A IL 108147A IL 10814793 A IL10814793 A IL 10814793A IL 10814793 A IL10814793 A IL 10814793A IL 108147 A IL108147 A IL 108147A
Authority
IL
Israel
Prior art keywords
dopa
ethyl ester
pharmaceutical composition
composition
solution
Prior art date
Application number
IL10814793A
Other languages
English (en)
Hebrew (he)
Other versions
IL108147A0 (en
Original Assignee
Teva Pharma
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Yissum Res Dev Co filed Critical Teva Pharma
Publication of IL108147A0 publication Critical patent/IL108147A0/xx
Publication of IL108147A publication Critical patent/IL108147A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL10814793A 1992-12-24 1993-12-22 APOD-L ethyl ester preparations and their preparation IL108147A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/995,847 US5354885A (en) 1992-12-24 1992-12-24 Process for preparing ethyl ester of L-DOPA

Publications (2)

Publication Number Publication Date
IL108147A0 IL108147A0 (en) 1994-04-12
IL108147A true IL108147A (en) 1998-09-24

Family

ID=25542272

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10814793A IL108147A (en) 1992-12-24 1993-12-22 APOD-L ethyl ester preparations and their preparation

Country Status (21)

Country Link
US (2) US5354885A (no)
EP (2) EP0610595B1 (no)
JP (1) JPH07285860A (no)
CN (1) CN1083262C (no)
AT (2) ATE196081T1 (no)
AU (1) AU684053B2 (no)
CA (1) CA2112160A1 (no)
CY (1) CY2214B1 (no)
DE (2) DE69329400T2 (no)
DK (2) DK0867179T3 (no)
ES (2) ES2150294T3 (no)
FI (1) FI107994B (no)
GR (2) GR3030073T3 (no)
HK (1) HK1012577A1 (no)
HU (1) HU218906B (no)
IL (1) IL108147A (no)
LV (1) LV12766B (no)
NO (1) NO305932B1 (no)
NZ (1) NZ250541A (no)
PT (1) PT867179E (no)
ZA (1) ZA939573B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
WO1997016181A1 (en) * 1995-11-03 1997-05-09 University Of Kentucky Method for the intranasal administration of l-dopa prodrugs
ATE219358T1 (de) * 1995-11-06 2002-07-15 Somerset Pharmaceuticals Inc Sublinguale und bukkale verabreichung von selegilin
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
AU768154B2 (en) * 1996-10-13 2003-12-04 Neuroderm Ltd Treatment of Parkinson's disease
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
US6166081A (en) * 1997-10-09 2000-12-26 Kushnir; Moshe Methods and apparatus for treatment of Parkinson's disease
BR9908713A (pt) 1998-03-16 2000-11-21 Somerset Pharmaceuticals Inc Uso de selegilina ou desmetil-selegilina para tratamento de feridas, queimaduras e danos dermatológicos
IL143071A0 (en) * 1998-11-10 2002-04-21 Teva Pharma Dispersible compositions containing l-dopa ethyl ester
IL143070A (en) * 1998-11-10 2004-03-28 Teva Pharma Process for the manufacture of l-dopa ethyl ester
RU2157196C1 (ru) * 1999-06-17 2000-10-10 Васильев Виталий Николаевич Фармацевтическая композиция в.н. васильева для восстановления функции симпатико-адреналовой системы, способ оценки индивидуальной эффективности этой композиции для терапии пациентов
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
AU2002340470A1 (en) * 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
WO2003042136A2 (en) * 2001-11-13 2003-05-22 Teva Pharmaceutical Industries, Ltd. Process for the production of l-dopa ethyl ester
ES2609482T3 (es) 2002-03-20 2017-04-20 Civitas Therapeutics, Inc. Administración pulmonar de levodopa
US6930137B2 (en) * 2002-05-31 2005-08-16 Fina Technology, Inc. Method of improving blown film processing performance and physical properties
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
WO2004069146A2 (en) * 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
WO2004096141A2 (en) * 2003-04-25 2004-11-11 Indevus Pharmaceuticals, Inc. Method for promoting uninterrupted sleep by administration of trospium chloride
KR100525358B1 (ko) * 2003-08-21 2005-11-04 주식회사 이엔에프테크놀로지 카르복실 벤조트리아졸 알킬에스테르의 제조방법
EP1670450B8 (en) * 2003-08-29 2011-03-23 Centocor Ortho Biotech Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
MXPA06003725A (es) * 2003-10-08 2006-06-23 Mallinckrodt Inc Solucion de fenidato de metilo y metodos asociados de administracion y produccion.
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
HUE028777T2 (en) * 2006-02-17 2017-01-30 Ratiopharm Gmbh Deuterated catecholamine derivatives and medicaments containing these compounds
CN101623278B (zh) * 2008-07-09 2013-02-27 北京德众万全药物技术开发有限公司 一种含有左旋多巴和盐酸苄丝肼的药物组合物
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
AU2016313138A1 (en) * 2015-08-27 2018-03-15 Prexton Therapeutics Sa Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
EP3518920A1 (en) 2016-09-29 2019-08-07 Berlirem GmbH L-dopa derivatives for the treatment of neurological diseases
ES2965284T3 (es) 2021-02-09 2024-04-11 Biobab R&D S L Método y uso de un enantiómero de 3,4-dihidroxifenilalanina (DOPA) para potenciar el atractivo de las plantas para los insectos beneficiosos

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA716958B (en) * 1970-10-30 1973-01-31 Hoffmann La Roche Phenylalanine amides
US3803120A (en) * 1971-09-28 1974-04-09 Hoffmann La Roche Di-and tripeptides of 3-(3,4-dihydroxyphenyl)-alanine
US3939253A (en) * 1973-11-02 1976-02-17 Interx Research Corporation Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
US4035507A (en) * 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4771073A (en) * 1985-12-30 1988-09-13 Merck & Co., Inc. Rectally absorbable form of L-dopa
ATE76747T1 (de) * 1986-06-10 1992-06-15 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.

Also Published As

Publication number Publication date
DK0867179T3 (da) 2000-11-06
PT867179E (pt) 2000-12-29
CA2112160A1 (en) 1994-06-25
HU9303748D0 (en) 1994-04-28
ES2132170T3 (es) 1999-08-16
DE69324466T2 (de) 1999-11-25
ZA939573B (en) 1994-08-11
AU684053B2 (en) 1997-12-04
ATE178793T1 (de) 1999-04-15
IL108147A0 (en) 1994-04-12
HUT68498A (en) 1995-06-28
NO934768L (no) 1994-06-27
LV12766A (lv) 2001-12-20
EP0610595B1 (en) 1999-04-14
CN1083262C (zh) 2002-04-24
NO934768D0 (no) 1993-12-22
DE69329400T2 (de) 2001-01-18
FI935847A (fi) 1994-06-25
NO305932B1 (no) 1999-08-23
LV12766B (en) 2002-03-20
FI107994B (fi) 2001-11-15
EP0867179B1 (en) 2000-09-06
HK1012577A1 (en) 1999-08-06
EP0610595A3 (en) 1994-09-21
CN1094950A (zh) 1994-11-16
GR3034867T3 (en) 2001-02-28
DE69324466D1 (de) 1999-05-20
HU218906B (hu) 2000-12-28
ES2150294T3 (es) 2000-11-16
JPH07285860A (ja) 1995-10-31
AU5257793A (en) 1994-07-07
DK0610595T3 (da) 1999-10-25
CY2214B1 (en) 2002-11-08
US5525631A (en) 1996-06-11
DE69329400D1 (de) 2000-10-12
EP0867179A1 (en) 1998-09-30
GR3030073T3 (en) 1999-07-30
FI935847A0 (fi) 1993-12-23
ATE196081T1 (de) 2000-09-15
NZ250541A (en) 1995-12-21
EP0610595A2 (en) 1994-08-17
US5354885A (en) 1994-10-11

Similar Documents

Publication Publication Date Title
US5354885A (en) Process for preparing ethyl ester of L-DOPA
US5607969A (en) L-DOPA ethyl ester to treat Parkinson's disease
RU2128160C1 (ru) Трометаминная соль (+)-(s)-2-(3-бензоилфенил)пропионовой кислоты, способ ее получения, фармацевтическая композиция
KR101411422B1 (ko) 중수소화 카테콜아민 유도체 및 이를 포함하는 의약품
EP2041108B1 (en) 4-hydroxythiobenzamide derivatives of drugs
US8889715B2 (en) Substituted pyridoxine-lactam carboxylate salts
US20230381181A1 (en) Methods for increasing sepiapterin plasma exposure
CA2884173C (en) Drug substance preparations, pharmaceutical compositions and dosage forms comprising s-(+)-flurbiprofen
US6201011B1 (en) Therapeutic agent for allergic dermatitis
EP0310259B1 (en) Eperisone as a hypotensive agent
CH643539A5 (fr) Derives de la l-cysteine et leur preparation, composes de deport du procede et medicament contenant les derives.
EP0555938A1 (fr) Utilisation de dérivés phénoxyacétiques pour la restauration des fonctions nerveuse
JP2022528355A (ja) Ｓ－（ｎ，ｎ－ジエチルカルバモイル）グルタチオンの塩形態
TW407141B (en) Vasomolol, an ultra short-acting and vasodilatory vanilloid type <beta>1- adrenoceptor antagonist
KR100378748B1 (ko) 말톨릴 파라-쿠마레이트, 이의 제조 방법 및 이를포함하는 치매 치료용 조성물
FR2470133A1 (fr) Nouveaux sels d'addition d'acides d'alcaloides de l'ergot et d'alcaloides du dihydro-ergot physiologiquement acceptables et amorphes aux rayons x, utiles comme medicaments et procede de leur preparation
FR2665634A1 (fr) Utilisation de derives de l'acide phenoxyacetique pour obtention d'un medicament destine a restituer le fonctionnement de la cellule nerveuse.
BE878563A (fr) Nouvelles alpha-alkyl-o-oxybenzylamines, leur preparation et leur application comme medicaments

Legal Events

Date Code Title Description
FF Patent granted
RH Patent void
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
KB Patent renewed